CRISPR CSO departs as Celgene continues to sell stock – FierceBiotech
FierceBiotech |
CRISPR CSO departs as Celgene continues to sell stock
FierceBiotech In the absence of Lundberg, Tony Ho, M.D., will oversee CRISPR's R&D activities. CRISPR appointed Ho, who previously worked at AstraZeneca and Merck, as its head of R&D in August. Ho inherits a broad preclinical pipeline of ex vivo and in vivo CRISPR … CRISPR Therapeutics Announces Transition of Bill Lundberg, MD Why Crispr Therapeutics AG Stock Bolted Higher in January Analysts Layout Best- And Worst-Case Scenarios: CRISPR Therapeutics AG (CRSP), Diodes Incorporated (DIOD) |
